Aridis Pharmaceuticals Inc. (ARDS)

Market Cap	16.46M
Revenue (ttm)	2.98M
Net Income (ttm)	-48.70M
Shares Out	17.70M
EPS (ttm)	-3.26
PE Ratio	n/a
Forward PE	2.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,403
Open	0.900
Previous Close	0.900
Day's Range	0.886 - 0.950
52-Week Range	0.680 - 4.340
Beta	1.25
Analysts	Buy
Price Target	12.24 (+1,216.1%)
Earnings Date	Nov 8, 2022

About ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caus...

• Industry: Biotechnology
• IPO Date: Aug 10, 2018
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: ARDS

Full Company Profile

Financial Performance

In 2021, ARDS's revenue was $1.54 million, an increase of 53.50% compared to the previous year's $1,000,000. Losses were -$42.19 million, 88.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 1,216.13% from the latest price.

Price Target

$12.24

(1,216.13% upside)

Analyst Consensus: Buy

Stock Forecasts